Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

DNA ligase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (12) Ligands for E3 Ligase (1) Androgen Receptor (1) Apoptosis (9) Bacterial (2) Biochemical Assay Reagents (1) Caspase (1) CDK (2) CRISPR/Cas9 (2) MDM-2/p53 (2) NEDD8-activating Enzyme (2) Parasite (2) PARP (1) PROTACs (4) Reactive Oxygen Species (1)
By Research Areas:	Cancer (17) Infection (4)

Inhibitors & Agonists

Screening Libraries

MCE Kits

Recombinant Proteins

Antibodies

Targets Recommended: DNA-PK DNA Methyltransferase DNA Stain DNA Alkylator/Crosslinker DNA/RNA Synthesis Ligands for E3 Ligase E3 Ligase Ligand-Linker Conjugates E1/E2/E3 Enzyme

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15586

L67 1 Publications Verification DNA ligase Inhibitor	DNA/RNA Synthesis Caspase Apoptosis Reactive Oxygen Species	Cancer
L67 (DNA Ligase Inhibitor) is a competitive **DNA ligase** inhibitor that effectively inhibits DNA ligases I/III (both IC₅₀ are 10 μM). L67 can cause nuclear DNA damage by reducing levels of mitochondrial DNA and increasing levels of mitochondrially-generated ROS. L67 also activates the Caspase 1-dependent apoptosis pathway in cancer cells, can be used in cancer research .

HY-15588

L189 3 Publications Verification	DNA/RNA Synthesis	Cancer
L189 is a **DNA ligase** inhibitor. L189 has inhibition effect for DNA Ligase I, III and IV with IC₅₀ values of 5 μM, 9 μM and 5 μM, respectively. L189 has no cytotoxicity and individually increase cell death. L189 can be used for the research of cancer .

HY-161152

DNA relaxation-IN-1	DNA/RNA Synthesis	Cancer
DNA relaxation-IN-1 (compound 27) is a DNA Ligase 1 (DNA Lig1) inhibitor, which inhibits DNA ligation and disrupts Lig I’s DNA relaxation activity. DNA relaxation-IN-1 combined with Topotecan (HY-13768) exhibits a synergistic antiproliferative effect on colorectal cancer cells .

HY-153215

MEL24	Ligands for E3 Ligase	Cancer
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies .

HY-148161

L82-G17	DNA/RNA Synthesis	Cancer
L82-G17 is an uncompetitive DNA ligase I (Lig I)-selective inhibitor. L82-G17 inhibits the third step of the ligation reaction, phosphodiester bond formation. L82-G17can be used as a probe of the catalytic activity .

HY-139297

SCR130	DNA/RNA Synthesis Apoptosis	Cancer
SCR130 is a SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor. SCR130 inhibits the end-joining of DNA in a Ligase IV-dependent manner. SCR130 is specific to Ligase IV, and shows minimal or no effect on Ligase III and Ligase I mediated joining. SCR130 induces cell apoptosis and has anticancer activity .

HY-15587

L82	DNA/RNA Synthesis	Cancer
L82 is a selective and uncompetitive DNA ligase 1 (DNA Lig1) inhibitor (hLig1 IC₅₀=12 μM). L82 shows anti-proliferative activity to breast cancer cells .

HY-150330

DNA ligase-IN-1	Bacterial DNA/RNA Synthesis	Infection
DNA ligase-IN-1 (Compound 1) is an inhibitor of bacterial NAD ⁺-dependent DNA ligase (LigA). DNA ligase-IN-1 effectively inhibits the growth of Staphylococcus aureus in vitro .

HY-150331

DNA ligase-IN-2	DNA/RNA Synthesis Bacterial	Infection
DNA ligase-IN-2 (compound 2) is a potent *LigA* inhibitor and inhibits the DNA-independent autoadenylation activity of both full-length LigA and a truncated enzyme, LigA:AD (IC₅₀=29 nM). DNA ligase-IN-2 effectively inhibits the growth of Staphylococcus aureus in vitro, with MIC valuse of 1, 1, and >64 μg/mL for S. aureus ATCC 29213, S. aureus ATCC 700699 and E. coli ATCC 25922, respectively .

HY-P3005

T4 DNA ligase	Biochemical Assay Reagents	Others
DNA ligase is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-107845

SCR7 pyrazine 10+ Cited Publications	CRISPR/Cas9 DNA/RNA Synthesis Apoptosis	Cancer
SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity .

HY-E70091

T4 RNA ligase	DNA/RNA Synthesis	Others
T4 RNA ligase is an ATP-dependent RNA ligase that can catalyze the formation of phosphodiester bonds between the 5'-P end and the 3'-OH end of single-stranded RNA, single-stranded DNA or single nucleotides between molecules or within molecules. T4 RNA ligase is used for enzymatic low ribonucleotide synthesis and 3′ end labeling of RNA. It is mainly used for RNA and RNA, but can also be used for RNA and single nucleotides .

HY-108640

HLI373	MDM-2/p53 Parasite Apoptosis	Infection Cancer
HLI373 is an efficacious Hdm2 inhibitor. HLI373 inhibits the ubiquitin ligase activity of Hdm2. HLI373 is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents . Antimalarial activity .

HY-108640A

HLI373 dihydrochloride	MDM-2/p53 Parasite Apoptosis	Infection Cancer
HLI373 dihydrochloride is an efficacious Hdm2 inhibitor. HLI373 dihydrochloride inhibits the ubiquitin ligase activity of Hdm2. HLI373 dihydrochloride is effective in inducing apoptosis of several tumor cells that are sensitive to DNA-damaging agents . Antimalarial activity .

HY-12742

SCR7	DNA/RNA Synthesis CRISPR/Cas9 Apoptosis	Cancer
SCR7 is an unstable form that can be autocyclized into a stable form SCR7 pyrazine (HY-107845). SCR7 pyrazine is a DNA ligase IV inhibitor that blocks nonhomologous end-joining (NHEJ) in a ligase IV-dependent manner. SCR7 pyrazine increases the efficiency of Cas9-mediated homology-directed repair (HDR). SCR7 pyrazine induces cell apoptosis and has anticancer activity .

HY-10484

Pevonedistat hydrochloride Maximum Cited Publications 157 Publications Verification MLN4924 hydrochloride	NEDD8-activating Enzyme Apoptosis	Cancer
Pevonedistat (MLN4924) hydrochloride is a potent and selective NEDD8-activating enzyme (NAE) inhibitor, with an IC₅₀ of 4.7 nM. Pevonedistat hydrochloride induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat hydrochloride suppresses the growth of human tumour xenografts in mice .

HY-70062

Pevonedistat Maximum Cited Publications 157 Publications Verification MLN4924	NEDD8-activating Enzyme Apoptosis	Cancer
Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC₅₀ of 4.7 nM. Pevonedistat induces the deregulation of S-phase DNA synthesis, thereby disrupting protein turnover mediated by cullin-RING ligase, leading to apoptosis of human tumor cells. Pevonedistat suppresses the growth of human tumour xenografts in mice .

HY-145479

PROTAC AR-V7 degrader-1	PROTACs Androgen Receptor	Cancer
PROTAC AR-V7 degrader-1 (Compound 6) is a potent, orally bioavailable and selective AR-V7 degrader with the DC₅₀ of 0.32 μM by recruiting VHL E3 ligase to Androgen receptor (AR) DNA binding domain (DBD) binder. PROTAC AR-V7 degrader-1 exhibits activity against 22Rv1 cell-line expressing AR-V7 with the EC₅₀ of 0.88 μM .

HY-168556

YJ9069	CDK PROTACs DNA/RNA Synthesis	Cancer
YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC₅₀ of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth. (Pink: CDK12/CDK13 degradation agent (HY-168658); Black: Linker (HY-W015967); Blue: ligand for E3 ligase (HY-103596)) .

HY-170620

PROTAC PARP1 degrader-4	PROTACs PARP	Cancer
PROTAC PARP1 degrader-4 (Compound 180055) is a selective PARP1 PROTAC degrader (DC₅₀ in T47D and MDA-MB-231 cell lines is 180 nM and 240 nM, respectively). PROTAC PARP1 degrader-4 promotes ubiquitination and degradation of PARP1 as well as inhibits PARP1 enzyme activity without a noticeable DNA trapping effect. PROTAC PARP1 degrader-4 inhibits tumors carrying BRCA mutations with a minor impact on the growth of normal cells (Pink: PARP1 ligand (HY-10617A); Blue: E3 ligase VHL ligand (HY-125845); Black: linker (HY-W014787)) .

HY-168555

YJ1206	CDK PROTACs Apoptosis	Cancer
YJ1206 is an orally active, selective CDK12/CDK13 PROTAC degrader with an IC₅₀ of 12.55 nM for in VCaP cells. YJ1206 increases DNA damage, induces apoptosis, and promotes tumor regression in orthotopic WA74 patient-derived xenograft (PDX) mice models of resistant prostate cancer. YJ1206 suppresses tumor growth in vivo in conjunction with AKT pathway inhibitors. YJ1206 is composed of the CDK12/CDK13 degradation agent (HY-168658), a linker (HY-W004328), and a VHL E3 ubiquitin ligase (HY-W453548). (Pink: Navitoclax; Blue: VHL ligand; Black: linker) .

Cat. No.	Product Name

HY-L050

Ubiquitination Compound Library	334 compounds
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 334 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Ubiquitination Compound Library

334 compounds

Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc.

MCE offers a unique collection of 334 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Cat. No.	Product Name

HY-K1049

*T4 DNA* Ligase (Fast)**
MCE T4 DNA Ligase (Fast) is produced by Escherichia coli carrying a T4 phage, catalyzes the formation of a phosphodiester bond between juxtaposed 5'-phosphate and 3'-hydroxyl termini in duplex DNA or RNA.

HY-KE8009

Taq DNA Ligase
This enzyme is a DNA ligase cloned from Thermus aquaticus HB8. It is expressed in E. coli using genetic recombination technology and purified and isolated multiple times.

Cat. No.	Compare	Product Name	Species	Source

HY-P703428

	birA Protein, B. subtilis (His) Bifunctional ligase/repressor BirA; Biotin--[acetyl-CoA-carboxylase] ligase; 6.3.4.15; Biotin--protein ligase; Biotin-[acetyl-CoA carboxylase] synthetase; birA; Bacillus subtilis (strain 168); DNA-binding; ligase; Repressor	Others	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83293

	LIG1 Antibody (YA3038) LIG1; DNA ligase 1; DNA ligase I; Polydeoxyribonucleotide synthase [ATP] 1	WB, IHC-F, IHC-P, ICC/IF	Human, Rat
	LIG1 Antibody (YA3038) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3038), targeting LIG1, with a predicted molecular weight of 102 kDa (observed band size: 102 kDa). LIG1 Antibody (YA3038) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human, rat background.

HY-P82045

	DNA Ligase I Antibody (YA1790) LIG1; DNA ligase 1; DNA ligase I; Polydeoxyribonucleotide synthase [ATP] 1	WB, IHC-P, ICC/IF	Human, Rat
	DNA Ligase I Antibody (YA1790) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1790), targeting DNA Ligase I, with a predicted molecular weight of 102 kDa (observed band size: 140 kDa). DNA Ligase I Antibody (YA1790) can be used for WB, IHC-P, ICC/IF experiment in human, rat background.

HY-P82954

	DNA Ligase IV Antibody (YA2699) LIG4; DNA ligase 4; DNA ligase IV; Polydeoxyribonucleotide synthase [ATP] 4	WB	Human
	DNA Ligase IV Antibody (YA2699) is a non-conjugated IgG antibody, targeting DNA Ligase IV, with a predicted molecular weight of 104 kDa (observed band size: 104 kDa). DNA Ligase IV Antibody (YA2699) can be used for WB experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.